Nizatidina [Spanish]

Nizatidina [Spanish] Brand names, Nizatidina [Spanish] Analogs

Nizatidina [Spanish] Brand Names Mixture

No information avaliable

Nizatidina [Spanish] Chemical_Formula

C₁₂H₂₁N₅O₂S₂

Nizatidina [Spanish] RX_link

http://www.rxlist.com/cgi/generic/nizat.htm

Nizatidina [Spanish] fda sheet

Nizatidina_[Spanish] FDA

Nizatidina [Spanish] msds (material safety sheet)

Nizatidina [Spanish] Synthesis Reference

R. P. Pioch, U.S. Pat. 4,375,547 (1982)

Nizatidina [Spanish] Molecular Weight

331.46 g/mol

Nizatidina [Spanish] Melting Point

203 ^oC

Nizatidina [Spanish] H₂O Solubility

10-33mg/mL

Nizatidina [Spanish] State

Solid

Nizatidina [Spanish] LogP

1.506

Nizatidina [Spanish] Dosage Forms

Capsule (150, 300 mg)

Nizatidina [Spanish] Indication

For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, active benign gastric ulcer, and active duodenal ulcer.

Nizatidina [Spanish] Pharmacology

Nizatidine is a competitive, reversible inhibitor of histamine at the histamine H2-receptors, particularly those in the gastric parietal cells. By inhibiting the action of histamine on stomach cells, nizatidine reduces stomach acid production. Nizatidine had no demonstrable antiandrogenic action. Full-dose therapy for the problems treated by nizatidine lasts no longer than 8 weeks. It has been demonstrated that treatment with a reduced dose of nizatidine is effective as maintenance therapy following healing of active duodenal ulcers.

Nizatidina [Spanish] Absorption

Rapid (bioavailability of nizatidine exceeds 70%)

Nizatidina [Spanish] side effects and Toxicity

Oral, rat LD₅₀: 301 mg/kg. Symptoms of overdose include cholinergic-type effects including lacrimation, salivation, emesis, miosis, and diarrhea.

Nizatidina [Spanish] Patient Information

Nizatidina [Spanish] Organisms Affected

Humans and other mammals